TY - JOUR
T1 - A novel focal lattice-tip catheter toggling between pulsed field energy and radiofrequency for atrial arrhythmia ablation
T2 - Results from a real-world, multicenter registry
AU - Vetta, Giampaolo
AU - Della Rocca, Domenico G.
AU - Sarkozy, Andrea
AU - Menè, Roberto
AU - Pannone, Luigi
AU - Almorad, Alexandre
AU - Sorgente, Antonio
AU - Betancur, Andres
AU - Marcon, Lorenzo
AU - Mouram, Sahar
AU - Stroker, Erwin
AU - Doundoulakis, Ioannis
AU - Eltsov, Ivan
AU - Kariki, Ourania
AU - Del Monte, Alvise
AU - Overeinder, Ingrid
AU - Audiat, Charles
AU - Nakasone, Kazutaka
AU - Sousonis, Vasileios
AU - Zaher, Wael
AU - Bala, Gezim
AU - Letsas, Kostantinos P.
AU - Combes, Stephane
AU - Sieira, Juan
AU - Efremidis, Michael
AU - Boveda, Serge
AU - de Asmundis, Carlo
AU - Chierchia, Gian Battista
N1 - Publisher Copyright:
© 2024 Heart Rhythm Society
PY - 2024/12/16
Y1 - 2024/12/16
N2 - Background: A novel focal lattice-tip catheter allowing the delivery of either pulsed field (PF) or radiofrequency (RF) energy has recently received regulatory approval. The technology features a proprietary 3-dimensional electroanatomic mapping system. Objective: We describe the first real-world and multicenter experience. Methods: Consecutive AF patients undergoing first-time or redo atrial tachyarrhythmia ablation with the Affera system were prospectively enrolled at 3 different centers. PF was the only energy source allowed when ablating the posterior left atrium; anterior applications were performed with either RF (PF/RF strategy) or PF (PF/PF strategy) on the basis of the operator's preference. The primary efficacy end point included acute electrical isolation of pulmonary veins and posterior wall or bidirectional block in case of linear lesions. Results: The study included 130 patients (mean age, 67 ± 10 years; 63.8% [n = 83] male; 61.5% [n = 80] nonparoxysmal AF; 55.4% first-time AF ablation). First-time pulmonary vein isolation was performed in 72 patients: RF/PF in 13 (18.1%) patients and PF/PF in the remaining 59 (81.9%); first-pass isolation for pulmonary vein and posterior wall was achieved in 100% of cases. A total of 289 ablation lines were performed (roof line, 91 patients; inferior line, 83 patients; anterior mitral line, 32 patients; posterior mitral line, 45 patients; cavotricuspid isthmus line, 38 patients). First-pass isolation and primary efficacy end point were 96.2% (roof line, 100%; inferior line, 100%; anterior mitral line, 96.9%; posterior mitral line, 84.4%; cavotricuspid isthmus, 92.1%) and 100%, respectively. We had 2 (1.5%) major complications: 1 ST-segment elevation at the inferolateral leads requiring intracoronary administration of nitrate and 1 complete atrioventricular block. Conclusion: Catheter ablation with a novel 9-mm lattice-tip catheter confirmed high efficacy and safety in a real-world scenario.
AB - Background: A novel focal lattice-tip catheter allowing the delivery of either pulsed field (PF) or radiofrequency (RF) energy has recently received regulatory approval. The technology features a proprietary 3-dimensional electroanatomic mapping system. Objective: We describe the first real-world and multicenter experience. Methods: Consecutive AF patients undergoing first-time or redo atrial tachyarrhythmia ablation with the Affera system were prospectively enrolled at 3 different centers. PF was the only energy source allowed when ablating the posterior left atrium; anterior applications were performed with either RF (PF/RF strategy) or PF (PF/PF strategy) on the basis of the operator's preference. The primary efficacy end point included acute electrical isolation of pulmonary veins and posterior wall or bidirectional block in case of linear lesions. Results: The study included 130 patients (mean age, 67 ± 10 years; 63.8% [n = 83] male; 61.5% [n = 80] nonparoxysmal AF; 55.4% first-time AF ablation). First-time pulmonary vein isolation was performed in 72 patients: RF/PF in 13 (18.1%) patients and PF/PF in the remaining 59 (81.9%); first-pass isolation for pulmonary vein and posterior wall was achieved in 100% of cases. A total of 289 ablation lines were performed (roof line, 91 patients; inferior line, 83 patients; anterior mitral line, 32 patients; posterior mitral line, 45 patients; cavotricuspid isthmus line, 38 patients). First-pass isolation and primary efficacy end point were 96.2% (roof line, 100%; inferior line, 100%; anterior mitral line, 96.9%; posterior mitral line, 84.4%; cavotricuspid isthmus, 92.1%) and 100%, respectively. We had 2 (1.5%) major complications: 1 ST-segment elevation at the inferolateral leads requiring intracoronary administration of nitrate and 1 complete atrioventricular block. Conclusion: Catheter ablation with a novel 9-mm lattice-tip catheter confirmed high efficacy and safety in a real-world scenario.
KW - Atrial fibrillation
KW - Catheter ablation
KW - Cavotricuspid isthmus
KW - Lattice tip
KW - Mitral isthmus
KW - Pulmonary vein isolation
KW - Pulsed field ablation
KW - Roof line
KW - Temperature controlled
UR - http://www.scopus.com/inward/record.url?scp=85214224508&partnerID=8YFLogxK
U2 - 10.1016/j.hrthm.2024.12.021
DO - 10.1016/j.hrthm.2024.12.021
M3 - Article
C2 - 39694305
AN - SCOPUS:85214224508
JO - Heart Rhythm
JF - Heart Rhythm
SN - 1547-5271
ER -